Stocks
Apteki 36.6 Financial Statements (APTK) |
|||||||
| Аптеки 36 и 6smart-lab.ru | % | 2021Q2 | 2021Q4 | 2022Q2 | 2022Q4 | 2023Q2 | |
|---|---|---|---|---|---|---|---|
| Report date | 30.08.2021 | 08.08.2023 | 29.08.2023 | 17.07.2023 | 29.08.2023 | ||
| Currency | RUB | RUB | RUB | RUB | RUB | ||
| Financial report URL | |||||||
| Revenue, bln rub | ? | 20.9 | 29.2 | 30.5 | |||
| EBITDA, bln rub | ? | 9.95 | |||||
| Net profit, bln rub | ? | -1.29 | 0.480 | 0.087 | |||
| OCF, bln rub | ? | -1.55 | 1.42 | ||||
| CAPEX, bln rub | ? | 0.225 | 0.520 | 0.570 | |||
| FCF, bln rub | ? | -4.20 | -1.24 | ||||
| Ordinary share dividend yield, % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
| Dividend payout ratio, % | 0% | 0% | 0% | ||||
| OPEX, bln rub | 9.34 | 10.00 | |||||
| Cost of production, bln rub | 13.7 | 19.1 | 20.3 | ||||
| Amortization, bln rub | 3.0 | 3.0 | |||||
| Employment expenses, bln rub | 3.90 | 4.20 | |||||
| Interest expenses, bln rub | 3.40 | 1.83 | 1.73 | ||||
| Assets, bln rub | 34.4 | 37.8 | 43.6 | 42.7 | |||
| Net Assets, bln rub | ? | -7.00 | -6.65 | -6.41 | -6.60 | ||
| Debt, bln rub | 21.6 | 21.6 | 18.9 | 18.7 | |||
| Cash, bln rub | 1.66 | 1.73 | 0.810 | 0.520 | |||
| Net debt, bln rub | 19.9 | 19.9 | 0.00 | 18.1 | 18.1 | ||
| Ordinary share price, rub | 13.9 | 14.0 | 12.4 | 11.6 | 13.5 | ||
| Number of ordinary shares, mln | 2 331 | 2 331 | 2 331 | 2 331 | 2 331 | ||
| Market cap, bln rub | 32.4 | 32.5 | 28.8 | 27.0 | 31.4 | ||
| EV, bln rub | ? | 52.3 | 52.4 | 28.8 | 45.1 | 49.6 | |
| Book value, bln rub | -19.2 | -19.5 | 0.00 | -19.9 | -19.9 | ||
| EPS, rub | ? | -0.55 | 0.00 | 0.21 | 0.00 | 0.04 | |
| FCF/share, rub | 0.00 | 0.00 | -1.80 | 0.00 | -0.53 | ||
| BV/share, rub | -8.26 | -8.37 | 0.00 | -8.54 | -8.53 | ||
| EBITDA margin, % | ? | 47.7% | 0.0% | 0.0% | |||
| Net margin, % | ? | -6.2% | 1.6% | 0.3% | |||
| FCF yield, % | ? | 0.0% | 0.0% | -14.6% | -15.6% | -3.9% | |
| ROE, % | ? | -107.0% | 19.4% | -7.5% | -1.3% | ||
| ROA, % | ? | 21.7% | -3.4% | 1.1% | 0.2% | ||
| P/E | ? | 4.33 | -25.2 | 60.1 | 56.2 | 361.3 | |
| P/FCF | -6.87 | -6.42 | -25.3 | ||||
| P/S | ? | 0.96 | 1.56 | 0.99 | 0.92 | 1.03 | |
| P/BV | ? | -1.68 | -1.67 | -1.35 | -1.58 | ||
| EV/EBITDA | ? | 13.0 | 5.27 | ||||
| Debt/EBITDA | 4.95 | 2.00 | |||||
| R&D/CAPEX, % | 0.00% | 0.00% | 0.00% | ||||
| CAPEX/Revenue, % | 1% | 2% | 2% | ||||
| Apteki 36.6 shareholders | |||||||
